Investor Presentaiton
19
FY2021 H1 Reconciliation from Reported to Core
REPORTED TO CORE ADJUSTMENTS
(Billion JPY)
REPORTED
Amortization Impairment
of
of
intangible intangible
assets
assets
Other
operating
income/
expenses
Sale of Japan
diabetes
portfolio
Irish
Tax
Assessment
1
CORE
Others
Revenue
Cost of sales
Gross profit
1,794.4
(133.0)
1,661.4
(517.1)
0.6
22.3
(494.1)
1,277.4
(132.4)
22.3
1,167.2
SG&A expenses
(431.9)
1.0
2.1
(428.7)
R&D expenses
(254.1)
1.3
(252.8)
Amortization of intangible assets
associated with products
(204.1)
204.1
Impairment losses on intangible assets associated
with products
(1.5)
1.5
Other operating income
19.5
(18.8)
(0.7)
Other operating expenses
(59.4)
59.4
Operating profit
346.0
204.1
1.5
40.6
(131.4)
25.0
485.7
Margin
19.3%
29.2%
Finance income and (expenses), net
Share of profit (loss) of investments accounted for
using the equity method
(58.0)
(0.4)
(58.5)
(3.5)
6.4
2.8
Profit before tax
284.4
Tax expenses
(100.7)
204.1
(45.5)
1.5
40.6
(0.5)
(11.5)
(131.4)
40.2
31.0
430.1
63.7
(39.9)
(94.2)
Non-controlling interests
(0.1)
(0.1)
Net profit attributable to owners of the Company
EPS (yen)
183.6
158.6
0.9
29.2
(91.2)
63.7
(9.0)
335.9
117
214
Number of shares (millions)
1,568
1,568
*1 Tax charges of 63.7 billion JPY arising from the tax assessment involving Irish taxation ofthe breakfee Shire received from AbbVie in connection with the
terminated offer to acquire Shire made by AbbVie in 2014, net of 0.5 billion JPY of associated tax benefit.
TakedaView entire presentation